Table 2.
Comparison between clinical, histopathological and prognostic variables adjusted for EBV infection status.
| Characteristic | EBV Positive n = 36 (%) |
EBV Negative n = 52 (%) |
p |
|---|---|---|---|
| Sex | 0.084 | ||
| Male | 24 (67) | 25 (48) | |
| Female | 12 (23) | 27 (52) | |
| Age (years) | 0.011 | ||
| <30 | 6 (17) | 22 (42) | |
| ≥30 | 30 (83) | 30 (58) | |
| Histological subtype | <0.001 | ||
| NS | 13 (36) | 42 (81) | |
| MC | 15 (42) | 1 (2) | |
| LR | 5 (14) | 3 (5) | |
| NOS | 3 (8) | 6 (12) | |
| Ann Arbor stage | 0.089 | ||
| I | 2 (6) | 0 (0) | |
| II | 10 (28) | 26 (50) | |
| III | 5 (14) | 5 (10) | |
| IV | 19 (52) | 21 (40) | |
| B symptoms at diagnosis | 0.056 | ||
| Absent | 10 (28) | 25 (48) | |
| Present | 26 (72) | 27 (52) | |
| Bulky disease | 0.066 | ||
| Absent | 34 (95) | 42 (81) | |
| Present | 2 (5) | 10 (19) | |
| IPS | 0.023 | ||
| 0–2 | 14 (39) | 33 (63) | |
| 3–7 | 22 (61) | 19 (37) | |
| GHSG | 0.112 | ||
| Limited stages | 4 (11) | 3 (6) | |
| Intermediate stages | 3 (8) | 13 (25) | |
| Advanced stages | 29 (81) | 36 (69) | |
| Response to therapy | 0.925 | ||
| Complete remission | 28 (78) | 40 (77) | |
| Refractory/relapsed | 8 (22) | 12 (23) |
NS, Nodular sclerosis; MC, Mixed cellularity; LR, Lymphocyte-rich; NOS, Not otherwise specified; EBV-LMP1, Epstein–Barr Virus Latent Membrane Protein 1; IPS, International Prognostic Score; GSHG, German Hodgkin Study Group, Cologne, Germany. Boldface font indicates statistical significance (p < 0.05).